HTHirokazu Tanaka

Hirokazu Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hirokazu Tanaka has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Prognostic Value of Circulating Tumor DNA for Clinical Outcomes in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis

    by Do Tung Dac, Hirokazu Tanaka, Akiyoshi Takami, Jorge Luis Espinoza

    Relapse remains the leading cause of treatment failure following hematopoietic cell transplantation (HCT) for hematologic malignancies. Circulating tumor DNA (ctDNA) has emerged as a promising minimally invasive biomarker for measurable residual disease (MRD) assessment and early relapse detection; however, the prognostic significance of ctDNA in the post-transplant setting has not been comprehensively synthesized. We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines and registered the protocol in PROSPERO (CRD420261392100). PubMed, Embase, Web of Science, EBSCO, Cochrane CENTRAL, and supplementary sources were searched through November 2025. Eligible studies evaluated tumor-specific ctDNA or tumor-informed/tumor-associated cfDNA in patients undergoing allogeneic or autologous HCT for hematologic malignancies. Random-effects meta-analyses were performed for relapse/progression, overall survival (OS), and relapse-free/progression-free survival (RFS/PFS). Studies evaluating total cfDNA quantity, methylation-based cfDNA profiling, cfRNA, or chimerism-only monitoring were synthesized narratively. Ten observational cohort studies comprising 883 patients met inclusion criteria. Across acute leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes, ctDNA/cfDNA positivity was consistently associated with adverse outcomes. The pooled hazard ratio (HR) for relapse or disease progression was 12.57 (95% CI: 4.59–34.46; p < 0.001), while pooled HRs were 7.45 (95% CI: 4.11–13.48; p < 0.001) for OS and 4.46 (95% CI: 2.22–8.97; p < 0.001) for RFS/PFS. Although statistical heterogeneity was low, interpretation was limited by the relatively small number of studies contributing to each pooled endpoint. Narrative evidence additionally suggested that broader circulating nucleic acid approaches may provide complementary information regarding graft-versus-host disease, infection, and other post-transplant complications. Tumor-specific ctDNA positivity is consistently associated with increased relapse risk and inferior survival outcomes following HCT. These findings support further investigation of ctDNA-based MRD monitoring as a promising non-invasive biomarker for post-transplant molecular surveillance and risk stratification. However, prospective multicenter validation studies, assay standardization, and ctDNA-guided interventional trials remain necessary before routine clinical implementation can be recommended.

  • Open Access

    Clonal Complexity Defines Distinct Tumor‐Intrinsic Biology and Prognosis in Diffuse Large B‐Cell Lymphoma

    by Takahiro Haeno, Kazuko Sakai, Shuji Minamoto, Daiki Nakatsu, Marco A. De Velasco, Shinya Rai, Hirokazu Tanaka, Itaru Matsumura, Kazuto Nishio

    Background: Intratumor heterogeneity (ITH), characterized by the coexistence of genetically distinct subclones within a tumor, has been associated with adverse clinical outcomes in various cancers. However, the clinical and biological implications of ITH in diffuse large B‐cell lymphoma (DLBCL) are still incompletely understood. Materials & Methods: In this study, we applied a SNP‐array–based approach to assess the clonal complexity in formalin‐fixed, paraffin‐embedded tumor specimens obtained from newly diagnosed patients with advanced‐stage DLBCL ( n = 74) by calculating the clonal composition (CC) number. Rseults: Patients with Poly‐CC tumors (CC ≥ 1), which accounted for 79.7% of the cases, had a 5‐year event‐free survival rate of 38.9%, compared with 69.1% in those with Mono‐CC tumors (CC = 0) (Log‐rank p = 0.0520). This association reached statistical significance in the activated B‐cell (ABC) subtype ( n = 35, Log‐rank p = 0.0450) but not in the germinal center B‐cell (GCB) subtype ( n = 30, Log‐rank p = 0.910). Gene set enrichment analysis revealed upregulation of cell cycle–related pathways in Poly‐CC tumors, consistent with the significantly higher Ki‐67 positivity rate than in Mono‐CC tumors, as confirmed by immunohistochemistry ( p = 0.00227). Within the ABC subtype, Poly‐CC (Poly‐ABC) tumors exhibited more differentiated transcriptional states and enrichment of IRF4‐associated gene signatures as compared with Mono‐CC (Mono‐ABC) tumors. Conversely, IFN‐γ and IFN‐α response pathways and the IL‐6/JAK‐STAT3 signaling pathway were markedly suppressed in the Poly‐ABC tumors. Furthermore, Poly‐ABC tumors carried a significantly higher number of pathogenic mutations as compared with Mono‐ABC tumors ( p = 0.0147). Conclusion: These results suggest that clonal complexity captures tumor‐intrinsic features and biological diversity in DLBCL, especially in the ABC subtype, offering novel insights into the disease pathogenesis.

  • Open Access

    Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells

    by Aki Fujii-Hanamoto, Hirokazu Tanaka, Ko Fujimoto, Takahiro Haeno, Yoshiaki Miyake, Ryosuke Fujiwara, Takahiro Kumode, Kentaro Serizawa, Yasuyoshi Morita, Hitoshi Hanamoto, et al.

    Background: FLT3 mutations, including internal tandem duplication (ITD) and tyrosine kinase domain (TKD) point mutations, represent common genetic alterations in acute myeloid leukemia (AML), with FLT3-ITD associated with poor prognosis. Although FLT3 tyrosine kinase inhibitors (TKIs), such as quizartinib (Quiz) and gilteritinib, have improved clinical outcomes, secondary TKD mutations, particularly the gatekeeper mutation F691L, confer significant resistance. We previously demonstrated that chlorpromazine (CPZ), an antipsychotic drug, inhibits clathrin-mediated endocytosis and selectively suppresses the growth of cancer cells harboring mutant receptor tyrosine kinases. Methods: In this study, we examined the efficacy of CPZ in overcoming TKI resistance using Ba/F3 cells expressing FLT3-ITD or FLT3-ITD/F692L, the murine analog of F691L. Results: Quiz inhibited proliferation of FLT3-ITD cells but was ineffective against FLT3-ITD/F692L cells. CPZ suppressed growth in both cell types. Co-treatment with CPZ and Quiz exhibited synergistic effects in FLT3-ITD cells, but not in FLT3-ITD/F692L cells. CPZ reduced STAT5 phosphorylation and modulated downstream signaling in FLT3-ITD cells, while only partially affecting STAT5 in FLT3-ITD/F692L cells. Expression of constitutively active STAT5 partially rescued CPZ-induced growth inhibition. Conclusions: These findings suggest that STAT5 suppression is a key mechanism of CPZ’s antileukemic activity and support its potential as a therapeutic strategy for FLT3-ITD-positive AML.


  • Depletion of Ppp6c in hematopoietic and vascular endothelial cells causes embryonic lethality and decreased hematopoietic potential

    by Ayumi Kondo, Hirokazu Tanaka, Shinya Rai, Hiroshi Shima, Itaru Matsumura, Toshio Watanabe

  • Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells

    by Ryosuke Fujiwara, Yasuhiro Taniguchi, Shinya Rai, Yoshio Iwata, Aki Fujii, Ko Fujimoto, Takahiro Kumode, Kentaro Serizawa, Yasuyoshi Morita, J. Luis Espinoza, et al.


  • CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence

    by Kentaro Serizawa, Hirokazu Tanaka, Takeshi Ueda, Ayano Fukui, Hiroaki Kakutani, Takahide Taniguchi, Hiroaki Inoue, Takahiro Kumode, Yasuhiro Taniguchi, Shinya Rai, et al.


  • C-type lectin-like receptor 2 specifies a functionally distinct subpopulation within phenotypically defined hematopoietic stem cell population that contribute to emergent megakaryopoiesis

    by Takahiro Kumode, Hirokazu Tanaka, Jorge Luis Esipinoza, Shinya Rai, Yasuhiro Taniguchi, Ryosuke Fujiwara, Keigo Sano, Kentaro Serizawa, Yoshio Iwata, Yasuyoshi Morita, et al.

    C-type lectin-like receptor 2 (CLEC-2) expressed on megakaryocytes plays important roles in megakaryopoiesis. We found that CLEC-2 was expressed in about 20% of phenotypical long-term hematopoietic stem cells (LT-HSCs), which expressed lower levels of HSC-specific genes and produced larger amounts of megakaryocyte-related molecules than CLEC-2low LT-HSCs. Although CLEC-2high LT-HSCs had immature clonogenic activity, cultured CLEC-2high LT-HSCs preferentially differentiated into megakaryocytes. CLEC-2high HSCs yielded 6.8 times more megakaryocyte progenitors (MkPs) and 6.0 times more platelets 2 weeks and 1 week after transplantation compared with CLEC-2low LT-HSCs. However, platelet yield from CLEC-2high HSCs gradually declined with the loss of MkPs, while CLEC-2low HSCs self-renewed long-term, indicating that CLEC-2high LT-HSCs mainly contribute to early megakaryopoiesis. Treatment with pI:C and LPS increased the proportion of CLEC-2high LT-HSCs within LT-HSCs. Almost all CLEC-2low LT-HSCs were in the G0 phase and barely responded to pI:C. In contrast, 54% of CLEC-2high LT-HSCs were in G0, and pI:C treatment obliged CLEC-2high LT-HSCs to enter the cell cycle and differentiate into megakaryocytes, indicating that CLEC-2high LT-HSCs are primed for cell cycle entry and rapidly yield platelets in response to inflammatory stress. In conclusion, CLEC-2high LT-HSCs appear to act as a reserve for emergent platelet production under stress conditions.


  • Open Access

    Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation

    by Shinya Rai, Hirokazu Tanaka, J. Luis Espinoza, Takahiro Kumode, Itaru Matsumura


  • Open Access

    Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V

    by Shinya Rai, Hirokazu Tanaka, Mai Suzuki, J. Luis Espinoza, Takahiro Kumode, Akira Tanimura, Takafumi Yokota, Kenji Oritani, Toshio Watanabe, Yuzuru Kanakura, et al.

    Mutated receptor tyrosine kinases (MT-RTKs) such as internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3 ITD) and a point mutation KIT D816V are driver mutations for acute myeloid leukemia (AML). Clathrin assembly lymphoid myeloid leukemia protein (CALM) regulates intracellular transport of RTKs, however, the precise role for MT-RTKs remains elusive. We here show that CALM knock down leads to severely impaired FLT3 ITD- or KIT D814V-dependent cell growth compared to marginal influence on wild-type FLT3- or KIT-mediated cell growth. An antipsychotic drug chlorpromazine (CPZ) suppresses the growth of primary AML samples, and human CD34+CD38- AML cells including AML initiating cells with MT-RTKs in vitro and in vivo. Mechanistically, CPZ reduces CALM protein at post transcriptional level and perturbs the intracellular localization of MT-RTKs, thereby blocking their signaling. Our study presents a therapeutic strategy for AML with MT-RTKs by altering the intracellular localization of MT-RTKs using CPZ.


  • Open Access

    Epstein–Barr Virus-Induced Post-Transplant Lymphoproliferative Disorder of the Central Nervous System Successfully Treated with Chemo-Immunotherapy

    by Hiroaki Inoue, Shinya Rai, Hirokazu Tanaka, J. Luis Espinoza, Maiko Komori-Inoue, Hiroaki Kakutani, Shuji Minamoto, Takahiro Kumode, Shoko Nakayama, Yasuhiro Taniguchi, et al.

    Aplastic anemia is a rare blood disease characterized by the destruction of the hematopoietic stem cells (HSC) in the bone marrow that, in the majority of cases, is caused by an autoimmune reaction. Patients with aplastic anemia are treated with immunosuppressive drugs and some of them, especially younger individuals with a donor available, can be successfully treated with hematopoietic stem cell transplantation (HSCT). We report here a rare case of post-transplant lymphoproliferative disorder (PTLD) associated with Epstein–Barr virus (EBV) reactivation in a 30-year-old female patient who underwent allogeneic HSCT for severe aplastic anemia. The PTLD, which was diagnosed 230 days after transplantation, was localized exclusively in the central nervous system (specifically in the choroid plexus) and manifested with obvious signs of intracranial hypertension. After receiving three cycles of high dose methotrexate (HD-MTX) combined with rituximab, the patient achieved a complete clinical recovery with normalization of blood cell counts, no evidence of EBV reactivation, and no associated neurotoxicity.